


SUPPLEMENTARY FIGURE 1 Plasma biomarkers derived from study CLCI699A2206 in primary aldosteronism. Panel

A: aldosterone; Panel B: potassium; Panel C: active renin; Panel D: sodium; Panel E: cortisol; Panel F: 11-deoxycortisol;

Panel G=adrenocorticotrophic hormone (ACTH); Panel H: 11-deoxycorticosterone

Footnote: REF, clinical reference value; BL, baseline value for the study start at day 0 and 1 (left columns) and on day 35, 1 week after the last dose (right column); LCI, LCI699 applied at 0.5 mg bid for 2 weeks with values for day 2 and day 8 followed by LCI699 applied at 1.0 mg bid for 2 weeks with values at day 15, day 22 and day 28 from left to right; W/O, washout value on day 29, the day after the last dose; bid, twice daily.



SUPPLEMENTARY FIGURE 2 Plasma biomarkers derived from study CLCI699A2215 in uncontrolled hypertension.

Panel A: aldosterone; Panel B: potassium; Panel C: plasma renin activity (PRA); Panel D: sodium; Panel E: cortisol; Panel F: 11-deoxycortisol; Panel G=adrenocorticotrophic hormone (ACTH); Panel H: 11-deoxycorticosterone

Footnote: REF, clinical reference value; BL, baseline value for the respective adjacent study arm to the right; LCI, LCI699 applied at 0.5 mg qd, 1.0 mg qd, 2.0 mg qd, 0.5 mg bid from left to right; PBO, placebo.

